Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Mar;39(3):305–311. doi: 10.1111/j.1365-2125.1995.tb04453.x

The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects.

K T Batty 1, T M Davis 1, K F Ilett 1, L J Dusci 1, S R Langton 1
PMCID: PMC1365008  PMID: 7619673

Abstract

1. The mechanism of the interaction between ciprofloxacin and theophylline was investigated in nine healthy subjects. 2. Subjects were given a single oral dose of theophylline (3.4 mg kg-1), before and after 60 h of ciprofloxacin therapy at a dose of 500 mg twice daily. 3. Ciprofloxacin reduced the oral clearance of theophylline by 19% (-7.73 +/- 6.42 ml kg-1 h-1 (95% confidence limits -12.66, -2.79)). Some subjects (group A, n = 4) showed little decrease in clearance (mean 4.4%; -1.6 +/- 0.7 ml kg-1 h-1 (-2.6, 0.5)), whereas others (group B, n = 5) showed a marked decrease (mean 30%; -12.7 +/- 3.7 ml kg-1 h-1 (-17.2, -8.1)). 4. Comparing groups A and B, the decrease in oral clearance of theophylline in group B could not be ascribed to differences in the AUC of ciprofloxacin. Group A subjects showed only slight inhibition of 1-demethylation (-12.8 +/- 5.5% (-21.5, -4.0)), while group B subjects showed a significantly greater inhibition of 1-demethylation (-49.9 +/- 9.8% (-62.1, -37.7)), 3-demethylation (-44.8 +/- 8.6% (-55.4, -34.1)) and 8-hydroxylation (-27.0 +/- 3.7% (-31.6, -22.4)). 5. The results suggest that inter-individual variability in the inhibition of theophylline metabolism by ciprofloxacin can be attributed to inter-individual differences in the level of CYP1A2 expression and/or in the degree of inhibition of hepatic CYP1A2 and CYP3A4. 6. The interaction between ciprofloxacin and theophylline can be clinically significant.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
305

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bader M. B. Role of ciprofloxacin in fatal seizures. Chest. 1992 Mar;101(3):883–884. doi: 10.1378/chest.101.3.883-b. [DOI] [PubMed] [Google Scholar]
  2. Bem J. L., Mann R. D. Danger of interaction between ciprofloxacin and theophylline. Br Med J (Clin Res Ed) 1988 Apr 16;296(6629):1131–1131. doi: 10.1136/bmj.296.6629.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berthou F., Flinois J. P., Ratanasavanh D., Beaune P., Riche C., Guillouzo A. Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab Dispos. 1991 May-Jun;19(3):561–567. [PubMed] [Google Scholar]
  4. Birkett D. J., Dahlqvist R., Miners J. O., Lelo A., Billing B. Comparison of theophylline and theobromine metabolism in man. Drug Metab Dispos. 1985 Nov-Dec;13(6):725–728. [PubMed] [Google Scholar]
  5. Campoli-Richards D. M., Monk J. P., Price A., Benfield P., Todd P. A., Ward A. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1988 Apr;35(4):373–447. doi: 10.2165/00003495-198835040-00003. [DOI] [PubMed] [Google Scholar]
  6. Davis R. L., Quenzer R. W., Kelly H. W., Powell J. R. Effect of the addition of ciprofloxacin on theophylline pharmacokinetics in subjects inhibited by cimetidine. Ann Pharmacother. 1992 Jan;26(1):11–13. doi: 10.1177/106002809202600102. [DOI] [PubMed] [Google Scholar]
  7. Fuhr U., Anders E. M., Mahr G., Sörgel F., Staib A. H. Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother. 1992 May;36(5):942–948. doi: 10.1128/aac.36.5.942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fuhr U., Strobl G., Manaut F., Anders E. M., Sörgel F., Lopez-de-Brinas E., Chu D. T., Pernet A. G., Mahr G., Sanz F. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Mol Pharmacol. 1993 Feb;43(2):191–199. [PubMed] [Google Scholar]
  9. Fuhr U., Wolff T., Harder S., Schymanski P., Staib A. H. Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes. Drug Metab Dispos. 1990 Nov-Dec;18(6):1005–1010. [PubMed] [Google Scholar]
  10. Grasela T. H., Jr, Dreis M. W. An evaluation of the quinolone-theophylline interaction using the Food and Drug Administration spontaneous reporting system. Arch Intern Med. 1992 Mar;152(3):617–621. [PubMed] [Google Scholar]
  11. Hendeles L., Iafrate R. P., Weinberger M. A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products. Clin Pharmacokinet. 1984 Mar-Apr;9(2):95–135. doi: 10.2165/00003088-198409020-00001. [DOI] [PubMed] [Google Scholar]
  12. Holden R. Probable fatal interaction between ciprofloxacin and theophylline. BMJ. 1988 Nov 19;297(6659):1339–1339. doi: 10.1136/bmj.297.6659.1339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ilett K. F., Castleden W. M., Vandongen Y. K., Stacey M. C., Butler M. A., Kadlubar F. F. Acetylation phenotype and cytochrome P450IA2 phenotype are unlikely to be associated with peripheral arterial disease. Clin Pharmacol Ther. 1993 Sep;54(3):317–322. doi: 10.1038/clpt.1993.153. [DOI] [PubMed] [Google Scholar]
  14. Karki S. D., Bentley D. W., Raghavan M. Seizure with ciprofloxacin and theophylline combined therapy. DICP. 1990 Jun;24(6):595–596. doi: 10.1177/106002809002400608. [DOI] [PubMed] [Google Scholar]
  15. Loi C. M., Parker B. M., Cusack B. J., Vestal R. Individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in male nonsmokers. Br J Clin Pharmacol. 1993 Sep;36(3):195–200. doi: 10.1111/j.1365-2125.1993.tb04216.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Niki Y., Soejima R., Kawane H., Sumi M., Umeki S. New synthetic quinolone antibacterial agents and serum concentration of theophylline. Chest. 1987 Oct;92(4):663–669. doi: 10.1378/chest.92.4.663. [DOI] [PubMed] [Google Scholar]
  17. Nix D. E., DeVito J. M., Whitbread M. A., Schentag J. J. Effect of multiple dose oral ciprofloxacin on the pharmacokinetics of theophylline and indocyanine green. J Antimicrob Chemother. 1987 Feb;19(2):263–269. doi: 10.1093/jac/19.2.263. [DOI] [PubMed] [Google Scholar]
  18. Prince R. A., Casabar E., Adair C. G., Wexler D. B., Lettieri J., Kasik J. E. Effect of quinolone antimicrobials on theophylline pharmacokinetics. J Clin Pharmacol. 1989 Jul;29(7):650–654. doi: 10.1002/j.1552-4604.1989.tb03394.x. [DOI] [PubMed] [Google Scholar]
  19. Raoof S., Wollschlager C., Khan F. A. Ciprofloxacin increases serum levels of theophylline. Am J Med. 1987 Apr 27;82(4A):115–118. [PubMed] [Google Scholar]
  20. Richardson J. P. Theophylline toxicity associated with the administration of ciprofloxacin in a nursing home patient. J Am Geriatr Soc. 1990 Mar;38(3):236–238. doi: 10.1111/j.1532-5415.1990.tb03497.x. [DOI] [PubMed] [Google Scholar]
  21. Robson R. A., Begg E. J., Atkinson H. C., Saunders D. A., Frampton C. M. Comparative effects of ciprofloxacin and lomefloxacin on the oxidative metabolism of theophylline. Br J Clin Pharmacol. 1990 Apr;29(4):491–493. doi: 10.1111/j.1365-2125.1990.tb03669.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Robson R. A., Matthews A. P., Miners J. O., McManus M. E., Meyer U. A., Hall P. M., Birkett D. J. Characterisation of theophylline metabolism in human liver microsomes. Br J Clin Pharmacol. 1987 Sep;24(3):293–300. doi: 10.1111/j.1365-2125.1987.tb03172.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Robson R. A. The effects of quinolones on xanthine pharmacokinetics. Am J Med. 1992 Apr 6;92(4A):22S–25S. doi: 10.1016/0002-9343(92)90303-s. [DOI] [PubMed] [Google Scholar]
  24. Rybak M. J., Bowles S. K., Chandrasekar P. H., Edwards D. J. Increased theophylline concentrations secondary to ciprofloxacin. Drug Intell Clin Pharm. 1987 Nov;21(11):879–881. doi: 10.1177/106002808702101106. [DOI] [PubMed] [Google Scholar]
  25. Sarkar M., Polk R. E., Guzelian P. S., Hunt C., Karnes H. T. In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes. Antimicrob Agents Chemother. 1990 Apr;34(4):594–599. doi: 10.1128/aac.34.4.594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Schwartz J., Jauregui L., Lettieri J., Bachmann K. Impact of ciprofloxacin on theophylline clearance and steady-state concentrations in serum. Antimicrob Agents Chemother. 1988 Jan;32(1):75–77. doi: 10.1128/aac.32.1.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Spivey J. M., Laughlin P. H., Goss T. F., Nix D. E. Theophylline toxicity secondary to ciprofloxacin administration. Ann Emerg Med. 1991 Oct;20(10):1131–1134. doi: 10.1016/s0196-0644(05)81391-5. [DOI] [PubMed] [Google Scholar]
  28. Thomson A. H., Thomson G. D., Hepburn M., Whiting B. A clinically significant interaction between ciprofloxacin and theophylline. Eur J Clin Pharmacol. 1987;33(4):435–436. doi: 10.1007/BF00637645. [DOI] [PubMed] [Google Scholar]
  29. Wijnands W. J., Vree T. B., Baars A. M., van Herwaarden C. L. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline. Drugs. 1987;34 (Suppl 1):159–169. doi: 10.2165/00003495-198700341-00034. [DOI] [PubMed] [Google Scholar]
  30. Wijnands W. J., Vree T. B., van Herwaarden C. L. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol. 1986 Dec;22(6):677–683. doi: 10.1111/j.1365-2125.1986.tb02957.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES